+357 96 030922
info@marketpublishers.com

Global Monoclonal Antibody for Asthma and COPD Market Growth 2026-2032

https://marketpublishers.com/r/G1E76DECB0DCEN.html
Date: October 2026
Pages: 116
Price: US$ 3,660.00 (Single User License)
ID: G1E76DECB0DCEN

Abstracts

The global Monoclonal Antibody for Asthma and COPD market size is predicted to grow from US$ 33490 million in 2025 to US$ 49430 million in 2032; it is expected to grow at a CAGR of 5.8% from 2026 to 2032.

Monoclonal antibodies for asthma and COPD are biologic agents targeting specific inflammatory pathways, neutralizing particular cytokines or receptors to modulate immune responses and improve airway inflammation and function. Representative drugs include Omalizumab, Mepolizumab, and Benralizumab, primarily used for the long-term management of patients with severe asthma, eosinophilic asthma, and certain COPD phenotypes. Upstream raw materials consist of high-purity recombinant antibody proteins, mammalian expression systems such as CHO cells, recombinant gene fragments, and associated buffers and excipients. Leading global suppliers include Biogen, Genentech (Roche), Amgen, GlaxoSmithKline (GSK), AstraZeneca, and Novartis, all of which possess advanced capabilities in antibody expression, purification, and large-scale manufacturing.

Downstream customers mainly comprise global pharmaceutical companies, hospitals, specialty clinics, and retail pharmacies, targeting patients with chronic respiratory diseases requiring long-term treatment. The primary end-users are patients with moderate-to-severe asthma or specific COPD phenotypes, as well as specialized respiratory medical institutions. With continuous advancements in biopharmaceutical technology and precision medicine, monoclonal antibody therapies are optimized for efficacy and safety, simultaneously driving upstream and downstream sectors, including expression system development, purification and fill-finish processes, cold-chain logistics, and clinical management services, thereby forming a complete high-value industrial ecosystem.

+357 96 030922
info@marketpublishers.com

In 2024, the global average price of monoclonal antibodies for asthma and COPD is approximately USD 1,031 per vial, with total sales reaching about 31.2 million vials.

United States market for Monoclonal Antibody for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Monoclonal Antibody for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Monoclonal Antibody for Asthma and COPD is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Monoclonal Antibody for Asthma and COPD players cover Teva Pharmaceuticals, Sanofi, AstraZeneca, GlaxoSmithKline, Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “Monoclonal Antibody for Asthma and COPD Industry Forecast” looks at past sales and reviews total world Monoclonal Antibody for Asthma and COPD sales in 2025, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibody for Asthma and COPD sales for 2026 through 2032. With Monoclonal Antibody for Asthma and COPD sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibody for Asthma and COPD industry.

This Insight Report provides a comprehensive analysis of the global Monoclonal Antibody for Asthma and COPD landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Monoclonal Antibody for Asthma and COPD portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Monoclonal Antibody for Asthma and COPD market.

+357 96 030922
info@marketpublishers.com

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibody for Asthma and COPD and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibody for Asthma and COPD.

This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibody for Asthma and COPD market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Type:

Reslizumab

Dupilumab

Benralizumab

Mepolizumab

Tezepelumab-ekko

Omalizumab

Others

Segmentation by Application:

Hospital

Clinic

+357 96 030922
info@marketpublishers.com

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

+357 96 030922
info@marketpublishers.com

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Teva Pharmaceuticals

Sanofi

AstraZeneca

GlaxoSmithKline

Roche

Amgen

Abacus Medicine

Swixx Biopharma

OriFarm

Aphria

+357 96 030922
info@marketpublishers.com

Novartis

Key Questions Addressed in this Report

What is the 10-year outlook for the global Monoclonal Antibody for Asthma and COPD market?

What factors are driving Monoclonal Antibody for Asthma and COPD market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Monoclonal Antibody for Asthma and COPD market opportunities vary by end market size?

How does Monoclonal Antibody for Asthma and COPD break out by Type, by Application?

+357 96 030922
info@marketpublishers.com

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Monoclonal Antibody for Asthma and COPD Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Monoclonal Antibody for Asthma and COPD by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Monoclonal Antibody for Asthma and COPD by Country/Region, 2021, 2025 & 2032
2.2 Monoclonal Antibody for Asthma and COPD Segment by Type
  2.2.1 Reslizumab
  2.2.2 Dupilumab
  2.2.3 Benralizumab
  2.2.4 Mepolizumab
  2.2.5 Tezepelumab-ekko
  2.2.6 Omalizumab
  2.2.7 Others
  2.2.8 Monoclonal Antibody for Asthma and COPD Sales by Type
    2.2.8.1 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2021-2026)
    2.2.8.2 Global Monoclonal Antibody for Asthma and COPD Revenue and Market Share by Type (2021-2026)
    2.2.8.3 Global Monoclonal Antibody for Asthma and COPD Sale Price by Type (2021-2026)
2.3 Monoclonal Antibody for Asthma and COPD Segment by Application
  2.3.1 Hospital
  2.3.2 Clinic

+357 96 030922
info@marketpublishers.com

2.3.3 Others
2.3.4 Monoclonal Antibody for Asthma and COPD Sales by Application
2.3.4.1 Global Monoclonal Antibody for Asthma and COPD Sale Market Share by Application (2021-2026)
2.3.4.2 Global Monoclonal Antibody for Asthma and COPD Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Monoclonal Antibody for Asthma and COPD Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Monoclonal Antibody for Asthma and COPD Breakdown Data by Company
3.1.1 Global Monoclonal Antibody for Asthma and COPD Annual Sales by Company (2021-2026)
3.1.2 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Company (2021-2026)
3.2 Global Monoclonal Antibody for Asthma and COPD Annual Revenue by Company (2021-2026)
3.2.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Company (2021-2026)
3.2.2 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Company (2021-2026)
3.3 Global Monoclonal Antibody for Asthma and COPD Sale Price by Company
3.4 Key Manufacturers Monoclonal Antibody for Asthma and COPD Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Monoclonal Antibody for Asthma and COPD Product Location Distribution
3.4.2 Players Monoclonal Antibody for Asthma and COPD Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR MONOCLONAL ANTIBODY FOR ASTHMA AND COPD BY GEOGRAPHIC REGION

4.1 World Historic Monoclonal Antibody for Asthma and COPD Market Size by Geographic Region (2021-2026)

+357 96 030922
info@marketpublishers.com

4.1.1 Global Monoclonal Antibody for Asthma and COPD Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Monoclonal Antibody for Asthma and COPD Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Monoclonal Antibody for Asthma and COPD Market Size by Country/Region (2021-2026)
4.2.1 Global Monoclonal Antibody for Asthma and COPD Annual Sales by Country/Region (2021-2026)
4.2.2 Global Monoclonal Antibody for Asthma and COPD Annual Revenue by Country/Region (2021-2026)
4.3 Americas Monoclonal Antibody for Asthma and COPD Sales Growth
4.4 APAC Monoclonal Antibody for Asthma and COPD Sales Growth
4.5 Europe Monoclonal Antibody for Asthma and COPD Sales Growth
4.6 Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales Growth

5 AMERICAS

5.1 Americas Monoclonal Antibody for Asthma and COPD Sales by Country
5.1.1 Americas Monoclonal Antibody for Asthma and COPD Sales by Country (2021-2026)
5.1.2 Americas Monoclonal Antibody for Asthma and COPD Revenue by Country (2021-2026)
5.2 Americas Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026)
5.3 Americas Monoclonal Antibody for Asthma and COPD Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Monoclonal Antibody for Asthma and COPD Sales by Region
6.1.1 APAC Monoclonal Antibody for Asthma and COPD Sales by Region (2021-2026)
6.1.2 APAC Monoclonal Antibody for Asthma and COPD Revenue by Region (2021-2026)
6.2 APAC Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026)
6.3 APAC Monoclonal Antibody for Asthma and COPD Sales by Application (2021-2026)

+357 96 030922
info@marketpublishers.com

6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Monoclonal Antibody for Asthma and COPD by Country
  7.1.1 Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2021-2026)
  7.1.2 Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2021-2026)
7.2 Europe Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026)
7.3 Europe Monoclonal Antibody for Asthma and COPD Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Monoclonal Antibody for Asthma and COPD by Country
  8.1.1 Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2021-2026)
8.2 Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026)
8.3 Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey

+357 96 030922
info@marketpublishers.com

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Monoclonal Antibody for Asthma and COPD
10.3 Manufacturing Process Analysis of Monoclonal Antibody for Asthma and COPD
10.4 Industry Chain Structure of Monoclonal Antibody for Asthma and COPD

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Monoclonal Antibody for Asthma and COPD Distributors
11.3 Monoclonal Antibody for Asthma and COPD Customer

12 WORLD FORECAST REVIEW FOR MONOCLONAL ANTIBODY FOR ASTHMA AND COPD BY GEOGRAPHIC REGION

12.1 Global Monoclonal Antibody for Asthma and COPD Market Size Forecast by Region
  12.1.1 Global Monoclonal Antibody for Asthma and COPD Forecast by Region (2027-2032)
  12.1.2 Global Monoclonal Antibody for Asthma and COPD Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Monoclonal Antibody for Asthma and COPD Forecast by Type (2027-2032)
12.7 Global Monoclonal Antibody for Asthma and COPD Forecast by Application

+357 96 030922
info@marketpublishers.com

(2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Teva Pharmaceuticals
13.1.1 Teva Pharmaceuticals Company Information
13.1.2 Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.1.3 Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Teva Pharmaceuticals Main Business Overview
13.1.5 Teva Pharmaceuticals Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.2.3 Sanofi Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.3.3 AstraZeneca Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 GlaxoSmithKline
13.4.1 GlaxoSmithKline Company Information
13.4.2 GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.4.3 GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 GlaxoSmithKline Main Business Overview
13.4.5 GlaxoSmithKline Latest Developments
13.5 Roche
13.5.1 Roche Company Information
13.5.2 Roche Monoclonal Antibody for Asthma and COPD Product Portfolios and

+357 96 030922
info@marketpublishers.com

Specifications
13.5.3 Roche Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Roche Main Business Overview
13.5.5 Roche Latest Developments
13.6 Amgen
13.6.1 Amgen Company Information
13.6.2 Amgen Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.6.3 Amgen Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Amgen Main Business Overview
13.6.5 Amgen Latest Developments
13.7 Abacus Medicine
13.7.1 Abacus Medicine Company Information
13.7.2 Abacus Medicine Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.7.3 Abacus Medicine Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Abacus Medicine Main Business Overview
13.7.5 Abacus Medicine Latest Developments
13.8 Swixx Biopharma
13.8.1 Swixx Biopharma Company Information
13.8.2 Swixx Biopharma Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.8.3 Swixx Biopharma Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Swixx Biopharma Main Business Overview
13.8.5 Swixx Biopharma Latest Developments
13.9 OriFarm
13.9.1 OriFarm Company Information
13.9.2 OriFarm Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.9.3 OriFarm Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 OriFarm Main Business Overview
13.9.5 OriFarm Latest Developments
13.10 Aphria
13.10.1 Aphria Company Information

+357 96 030922
info@marketpublishers.com

13.10.2 Aphria Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.10.3 Aphria Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Aphria Main Business Overview
13.10.5 Aphria Latest Developments
13.11 Novartis
13.11.1 Novartis Company Information
13.11.2 Novartis Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
13.11.3 Novartis Monoclonal Antibody for Asthma and COPD Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Novartis Main Business Overview
13.11.5 Novartis Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. Monoclonal Antibody for Asthma and COPD Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Monoclonal Antibody for Asthma and COPD Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Reslizumab
Table 4. Major Players of Dupilumab
Table 5. Major Players of Benralizumab
Table 6. Major Players of Mepolizumab
Table 7. Major Players of Tezepelumab-ekko
Table 8. Major Players of Omalizumab
Table 9. Major Players of Others
Table 10. Global Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 11. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2021-2026)
Table 12. Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2021-2026) & ($ million)
Table 13. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2021-2026)
Table 14. Global Monoclonal Antibody for Asthma and COPD Sale Price by Type (2021-2026) & (US$/Unit)
Table 15. Global Monoclonal Antibody for Asthma and COPD Sale by Application (2021-2026) & (K Units)
Table 16. Global Monoclonal Antibody for Asthma and COPD Sale Market Share by Application (2021-2026)
Table 17. Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2021-2026) & ($ million)
Table 18. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2021-2026)
Table 19. Global Monoclonal Antibody for Asthma and COPD Sale Price by Application (2021-2026) & (US$/Unit)
Table 20. Global Monoclonal Antibody for Asthma and COPD Sales by Company (2021-2026) & (K Units)
Table 21. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Company (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 22. Global Monoclonal Antibody for Asthma and COPD Revenue by Company (2021-2026) & ($ millions)
Table 23. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Company (2021-2026)
Table 24. Global Monoclonal Antibody for Asthma and COPD Sale Price by Company (2021-2026) & (US$/Unit)
Table 25. Key Manufacturers Monoclonal Antibody for Asthma and COPD Producing Area Distribution and Sales Area
Table 26. Players Monoclonal Antibody for Asthma and COPD Products Offered
Table 27. Monoclonal Antibody for Asthma and COPD Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Market M&A Activity & Strategy
Table 30. Global Monoclonal Antibody for Asthma and COPD Sales by Geographic Region (2021-2026) & (K Units)
Table 31. Global Monoclonal Antibody for Asthma and COPD Sales Market Share Geographic Region (2021-2026)
Table 32. Global Monoclonal Antibody for Asthma and COPD Revenue by Geographic Region (2021-2026) & ($ millions)
Table 33. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Geographic Region (2021-2026)
Table 34. Global Monoclonal Antibody for Asthma and COPD Sales by Country/Region (2021-2026) & (K Units)
Table 35. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Country/Region (2021-2026)
Table 36. Global Monoclonal Antibody for Asthma and COPD Revenue by Country/Region (2021-2026) & ($ millions)
Table 37. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country/Region (2021-2026)
Table 38. Americas Monoclonal Antibody for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 39. Americas Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2021-2026)
Table 40. Americas Monoclonal Antibody for Asthma and COPD Revenue by Country (2021-2026) & ($ millions)
Table 41. Americas Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 42. Americas Monoclonal Antibody for Asthma and COPD Sales by Application (2021-2026) & (K Units)

+357 96 030922
info@marketpublishers.com

Table 43. APAC Monoclonal Antibody for Asthma and COPD Sales by Region (2021-2026) & (K Units)
Table 44. APAC Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2021-2026)
Table 45. APAC Monoclonal Antibody for Asthma and COPD Revenue by Region (2021-2026) & ($ millions)
Table 46. APAC Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 47. APAC Monoclonal Antibody for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 48. Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 49. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2021-2026) & ($ millions)
Table 50. Europe Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 51. Europe Monoclonal Antibody for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 52. Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2021-2026) & (K Units)
Table 53. Middle East & Africa Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2021-2026)
Table 54. Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales by Type (2021-2026) & (K Units)
Table 55. Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales by Application (2021-2026) & (K Units)
Table 56. Key Market Drivers & Growth Opportunities of Monoclonal Antibody for Asthma and COPD
Table 57. Key Market Challenges & Risks of Monoclonal Antibody for Asthma and COPD
Table 58. Key Industry Trends of Monoclonal Antibody for Asthma and COPD
Table 59. Monoclonal Antibody for Asthma and COPD Raw Material
Table 60. Key Suppliers of Raw Materials
Table 61. Monoclonal Antibody for Asthma and COPD Distributors List
Table 62. Monoclonal Antibody for Asthma and COPD Customer List
Table 63. Global Monoclonal Antibody for Asthma and COPD Sales Forecast by Region (2027-2032) & (K Units)
Table 64. Global Monoclonal Antibody for Asthma and COPD Revenue Forecast by Region (2027-2032) & ($ millions)

+357 96 030922
info@marketpublishers.com

Table 65. Americas Monoclonal Antibody for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Americas Monoclonal Antibody for Asthma and COPD Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. APAC Monoclonal Antibody for Asthma and COPD Sales Forecast by Region (2027-2032) & (K Units)
Table 68. APAC Monoclonal Antibody for Asthma and COPD Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 69. Europe Monoclonal Antibody for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Europe Monoclonal Antibody for Asthma and COPD Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales Forecast by Country (2027-2032) & (K Units)
Table 72. Middle East & Africa Monoclonal Antibody for Asthma and COPD Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. Global Monoclonal Antibody for Asthma and COPD Sales Forecast by Type (2027-2032) & (K Units)
Table 74. Global Monoclonal Antibody for Asthma and COPD Revenue Forecast by Type (2027-2032) & ($ millions)
Table 75. Global Monoclonal Antibody for Asthma and COPD Sales Forecast by Application (2027-2032) & (K Units)
Table 76. Global Monoclonal Antibody for Asthma and COPD Revenue Forecast by Application (2027-2032) & ($ millions)
Table 77. Teva Pharmaceuticals Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 78. Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 79. Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Teva Pharmaceuticals Main Business
Table 81. Teva Pharmaceuticals Latest Developments
Table 82. Sanofi Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 83. Sanofi Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 84. Sanofi Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Sanofi Main Business

+357 96 030922
info@marketpublishers.com

Table 86. Sanofi Latest Developments
Table 87. AstraZeneca Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 88. AstraZeneca Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 89. AstraZeneca Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. AstraZeneca Main Business
Table 91. AstraZeneca Latest Developments
Table 92. GlaxoSmithKline Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 93. GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 94. GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. GlaxoSmithKline Main Business
Table 96. GlaxoSmithKline Latest Developments
Table 97. Roche Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 98. Roche Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 99. Roche Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Roche Main Business
Table 101. Roche Latest Developments
Table 102. Amgen Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 103. Amgen Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 104. Amgen Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Amgen Main Business
Table 106. Amgen Latest Developments
Table 107. Abacus Medicine Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 108. Abacus Medicine Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 109. Abacus Medicine Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 110. Abacus Medicine Main Business
Table 111. Abacus Medicine Latest Developments
Table 112. Swixx Biopharma Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 113. Swixx Biopharma Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 114. Swixx Biopharma Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Swixx Biopharma Main Business
Table 116. Swixx Biopharma Latest Developments
Table 117. OriFarm Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 118. OriFarm Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 119. OriFarm Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. OriFarm Main Business
Table 121. OriFarm Latest Developments
Table 122. Aphria Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 123. Aphria Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 124. Aphria Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Aphria Main Business
Table 126. Aphria Latest Developments
Table 127. Novartis Basic Information, Monoclonal Antibody for Asthma and COPD Manufacturing Base, Sales Area and Its Competitors
Table 128. Novartis Monoclonal Antibody for Asthma and COPD Product Portfolios and Specifications
Table 129. Novartis Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Novartis Main Business
Table 131. Novartis Latest Developments

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Monoclonal Antibody for Asthma and COPD
Figure 2. Monoclonal Antibody for Asthma and COPD Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Monoclonal Antibody for Asthma and COPD Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Monoclonal Antibody for Asthma and COPD Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Monoclonal Antibody for Asthma and COPD Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Monoclonal Antibody for Asthma and COPD Sales Market Share by Country/Region (2025)
Figure 10. Monoclonal Antibody for Asthma and COPD Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Reslizumab
Figure 12. Product Picture of Dupilumab
Figure 13. Product Picture of Benralizumab
Figure 14. Product Picture of Mepolizumab
Figure 15. Product Picture of Tezepelumab-ekko
Figure 16. Product Picture of Omalizumab
Figure 17. Product Picture of Others
Figure 18. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type in 2026
Figure 19. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2021-2026)
Figure 20. Monoclonal Antibody for Asthma and COPD Consumed in Hospital
Figure 21. Global Monoclonal Antibody for Asthma and COPD Market: Hospital (2021-2026) & (K Units)
Figure 22. Monoclonal Antibody for Asthma and COPD Consumed in Clinic
Figure 23. Global Monoclonal Antibody for Asthma and COPD Market: Clinic (2021-2026) & (K Units)
Figure 24. Monoclonal Antibody for Asthma and COPD Consumed in Others
Figure 25. Global Monoclonal Antibody for Asthma and COPD Market: Others (2021-2026) & (K Units)

+357 96 030922
info@marketpublishers.com

Figure 26. Global Monoclonal Antibody for Asthma and COPD Sale Market Share by Application (2025)
Figure 27. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application in 2026
Figure 28. Monoclonal Antibody for Asthma and COPD Sales by Company in 2026 (K Units)
Figure 29. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Company in 2026
Figure 30. Monoclonal Antibody for Asthma and COPD Revenue by Company in 2026 ($ millions)
Figure 31. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Company in 2026
Figure 32. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Geographic Region (2021-2026)
Figure 33. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Geographic Region in 2026
Figure 34. Americas Monoclonal Antibody for Asthma and COPD Sales 2021-2026 (K Units)
Figure 35. Americas Monoclonal Antibody for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 36. APAC Monoclonal Antibody for Asthma and COPD Sales 2021-2026 (K Units)
Figure 37. APAC Monoclonal Antibody for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 38. Europe Monoclonal Antibody for Asthma and COPD Sales 2021-2026 (K Units)
Figure 39. Europe Monoclonal Antibody for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 40. Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales 2021-2026 (K Units)
Figure 41. Middle East & Africa Monoclonal Antibody for Asthma and COPD Revenue 2021-2026 ($ millions)
Figure 42. Americas Monoclonal Antibody for Asthma and COPD Sales Market Share by Country in 2026
Figure 43. Americas Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2021-2026)
Figure 44. Americas Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 45. Americas Monoclonal Antibody for Asthma and COPD Sales Market Share

+357 96 030922
info@marketpublishers.com

by Application (2021-2026)
Figure 46. United States Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 47. Canada Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 48. Mexico Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 49. Brazil Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 50. APAC Monoclonal Antibody for Asthma and COPD Sales Market Share by Region in 2026
Figure 51. APAC Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2021-2026)
Figure 52. APAC Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 53. APAC Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 54. China Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 55. Japan Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 56. South Korea Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 57. Southeast Asia Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 58. India Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 59. Australia Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 60. China Taiwan Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 61. Europe Monoclonal Antibody for Asthma and COPD Sales Market Share by Country in 2026
Figure 62. Europe Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2021-2026)
Figure 63. Europe Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 64. Europe Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2021-2026)

+357 96 030922
info@marketpublishers.com

Figure 65. Germany Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 66. France Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 67. UK Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 68. Italy Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 69. Russia Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 70. Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2021-2026)
Figure 71. Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2021-2026)
Figure 72. Middle East & Africa Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2021-2026)
Figure 73. Egypt Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 74. South Africa Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 75. Israel Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 76. Turkey Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 77. GCC Countries Monoclonal Antibody for Asthma and COPD Revenue Growth 2021-2026 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of Monoclonal Antibody for Asthma and COPD in 2026
Figure 79. Manufacturing Process Analysis of Monoclonal Antibody for Asthma and COPD
Figure 80. Industry Chain Structure of Monoclonal Antibody for Asthma and COPD
Figure 81. Channels of Distribution
Figure 82. Global Monoclonal Antibody for Asthma and COPD Sales Market Forecast by Region (2027-2032)
Figure 83. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share Forecast by Region (2027-2032)
Figure 84. Global Monoclonal Antibody for Asthma and COPD Sales Market Share Forecast by Type (2027-2032)
Figure 85. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share

+357 96 030922
info@marketpublishers.com

Forecast by Type (2027-2032)
Figure 86. Global Monoclonal Antibody for Asthma and COPD Sales Market Share Forecast by Application (2027-2032)
Figure 87. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share Forecast by Application (2027-2032)

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Monoclonal Antibody for Asthma and COPD Market Growth 2026-2032
Product link: https://marketpublishers.com/r/G1E76DECB0DCEN.html
Price: US$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G1E76DECB0DCEN.html